Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.44 |
| ▸ | KDR | P35968 | 7/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759113 | 0.83 | KDM4E (0.48) | ALDH1A1DGAT1KDRNPC1RAB9A | |
| SCHEMBL12647972 | 0.81 | DGAT1 (0.48) | ALDH1A1DGAT1KDRNPC1RAB9A | |
| SCHEMBL2755165 | 0.81 | ALDH1A1 (0.45) | ALDH1A1DGAT1KDRNPC1RAB9A | |
| SCHEMBL12647975 | 0.78 | DGAT1 (0.43) | ALDH1A1DGAT1KDRNPC1RAB9A | |
| SCHEMBL12663993 | 0.78 | DGAT1 (0.55) | ALDH1A1DGAT1KDRNPC1RAB9A | |
| SCHEMBL236467 | 0.77 | RAB9A (0.64) | ALDH1A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL237019 | 0.74 | CYP1A2 (0.55) | ALDH1A1KDRP2RX7NPC1RAB9A | |
| SCHEMBL11545124 | 0.72 | DGAT1 (0.39) | ALDH1A1DGAT1KDRNPC1RAB9A | |
| SCHEMBL234660 | 0.71 | DGAT1 (0.49) | DGAT1KDR | |
| SCHEMBL235971 | 0.71 | DGAT1 (0.53) | DGAT1KDRNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406250-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | ALDH1A1 3980/4885DGAT1 2268/4885KDR 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.